Search Results - immunotherapy

35 Results

Sort By:

Novel Anti-mesothelin CAR for Use in Engineered Cell Therapies (UCLA Case No. 2023-281)

UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a nanobody-based CAR T cell platform with increased stability and cross-immunogenicity between human and mouse antigens. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered T cells to target and clear cancer cells....

Published: 3/6/2024 | Inventor(s): Yvonne Chen

Keywords(s): Cancer, CAR-T cell platform, CAR-T cell therapy, cell engineering, Immunotherapy, Mesothelin, nanobody, Nanoparticle

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Targeted Delivery of IFN-gamma Using Antibody Fusion Proteins (UCLA Case No. 2017-543)

UCLA researchers in the Departments of Microbiology, Immunology & Molecular Genetics (MIMG) and Medicine have developed antibody–cytokine fusion proteins that enable the targeted delivery of active interferon-gamma (IFNγ) for cancer treatment. Interferon-gamma (IFNγ), a type II interferon, is a cytokine released by both natural...

Published: 2/26/2024 | Inventor(s): Sherie Morrison, John Timmerman, Kham (Ryan) Trinh

Keywords(s): Antibody Delivery Platforms, Drug Delivery, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines

Category(s): Therapeutics, Platforms > Drug Delivery, Platforms > Drug Delivery > Antibody Delivery Platforms, Life Science Research Tools, Therapeutics > Immunology And Immunotherapy

New Fusion Molecule Based on Novel TAA Variant (UCLA Case No. 2007-217)

BACKGROUND: Renal cell carcinoma (RCC) affects approximately 39,000 Americans and causes an estimated 13,000 deaths per year. Metastatic RCC poses a therapeutic challenge because of its resistance to conventional modes of therapy. Approximately one third of RCC patients will present at the metastatic stage and one third of patients with localized disease...

Published: 2/16/2024 | Inventor(s): Arie Belldegrun, Zhenhua Li

Keywords(s): Cancer, Immunotherapy, Renal, Renal cell carcinoma, renal diseases

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Renal

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/15/2024 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

A T-Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2023-020)

UCLA researchers at the Departments of Medicine and Microbiology Immunology and Molecular Genetics have developed a novel bispecific antibody-based immunotherapy strategy for the treatment of Cytomegalovirus infections. BACKGROUND: The human cytomegalovirus (CMV) is a widespread virus estimated to infect 60% of American adults and nearly 100% of...

Published: 2/16/2024 | Inventor(s): Otto Yang

Keywords(s): Anti-CD3 antibodies, Bispecific antibodies, CD8 T cells, Human cytomegalovirus (CMV), Immunotherapy, Lymphocytes, T cell redirecting bispecific antibody (TRBA), Viral infection

Category(s): Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy

2023-009: Repurposing Native Cytokine Receptor Signaling for Adoptive T Cell Therapy of Cancer

SUMMARY: UCLA researchers in the Department of Radiation Oncology at the School of Medicine have identified a cytokine receptor endowing adoptively transferred T cells with new functions that enhance the potency of adoptively transferred T cells for the treatment of solid tumors, namely by restoring their functionality in the absence of conditioning...

Published: 7/19/2023 | Inventor(s): Anusha Kalbasi

Keywords(s): Cancer, Immunotherapy, Tumor

Category(s): Life Science Research Tools, Therapeutics

2018-680: Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA And CS1 For The Treatment Of Multiple Myeloma

SUMMARY UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American...

Published: 1/16/2024 | Inventor(s): Yvonne Chen, Eugenia Zah

Keywords(s): Hematology, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Therapeutics, Therapeutics > Hematology, Therapeutics > Immunology And Immunotherapy

2021-075 A New Drug Class Inhibits Illness and Death Due to Coronavirus Infection in Mice

Researchers from UCLA’s Department of Molecular and Medical Pharmacology have identified and validated a therapeutic target and an accompanying drug class which ameliorates illness and death due to Coronavirus infection. BACKGROUNDThere remains an urgent need for treatments that can reduce the symptoms for those infected by SARS-CoV-2, its future...

Published: 7/19/2023 | Inventor(s): Daniel Kaufman, Jide Tian

Keywords(s): Immunotherapy

Category(s): Therapeutics > Autoimmune, Therapeutics > Cardiovascular

2020-784 DEVELOPMENT OF A STING DELIVERING NANOPARTICLE FOR IMMUNOTHERAPY OF CANCER METASTASES TO THE LIVER

UCLA researchers in the Department of Nanomedicine have developed antigen presenting cells (APCs) targeting nanoparticles to deliver STING (stimulator of interferon genes) agonists to the liver for metastatic cancer treatment. BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and estimated to become the second leading...

Published: 7/19/2023 | Inventor(s): Andre Nel

Keywords(s): Drug Delivery, Immunotherapy, Nanoparticles, Oncology, Therapeutics & Vaccines

Category(s): Platforms > Drug Delivery, Therapeutics, Platforms > Drug Delivery > Nanoparticles, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Materials > Nanotechnology

2021-008 TARGETED NEOANTIGEN VACCINATION IN H3G34R/V GLIOMA

UCLA researchers in the Departments of Neurosurgery and Microbiology, Immunology, and Molecular Genetics have developed an immunotherapy treatment methodology for H3G34R/V high-grade glioma, providing an ability to be adapted toward a wide range of similar tumors.BACKGROUND:Over 3000 gliomas and other forms of brain cancer are diagnosed in children...

Published: 7/19/2023 | Inventor(s): Anthony Wang, Geoffrey Owens, Yi Xing, Robert Prins, Linda Liau, David Nathanson

Keywords(s): Immunotherapy, Oncology, Oncology Immunotherapy

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

1 2 3 4